onabotulinumtoxinA (Botox)

01/01/2015 - "Yet, nowadays there are treatments that have proven to be effective in cases of chronic migraine, such as OnabotulinumtoxinA. "
06/01/2002 - "Twenty-four of 29 patients (82.8 percent, p < 0.001) reported a positive response to the injection of Botox, 16 (55.2 percent, p < 0.001) observed complete elimination, eight (27.6 percent, p < 0.04) experienced significant improvement (at least 50 percent reduction in intensity or severity), and five (17.2 percent, not significant) did not notice a change in their migraine headaches. "
01/01/2013 - "The Phase III Research Evaluating Migraine Prophylaxis Therapy studies demonstrated onabotulinumtoxin A is effective in the preventive management of chronic migraine headaches. "
01/01/2015 - "Onabotulinumtoxin A (BoNTA) has been reported to be effective in the therapy for migraines. "
01/01/2015 - "OnabotulinumtoxinA is equally effective in patients with chronic migraine with or without analgesic overuse. "

08/01/2011 - "A significant reduction was recorded in the secondary end point, mean acute pain drug consumption at 12 weeks in onabotulinum toxin A-treated patients when compared with those with placebo (12.1 vs. 18.0; p = 0.03). "
12/01/2014 - "In this pilot open-label study, men with CSP who had failed medical management but experienced temporary pain relief from a standard cord block underwent a cord block with 100U Botox. "
02/13/2004 - "Specifically, we seek to assess the efficacy of Botox in reducing pain and to improve the cervical spine range of movement, during the 6-month trial period."
07/01/2009 - "Although its mechanism is unknown, Botox yielded a distinct improvement in perfusion and reduction in pain in patients failing conservative management. "
02/13/2004 - "The primary objective is to determine the efficacy of Botox in the management of musculoskeletal pain in whiplash associated disorders. "

01/01/2014 - "The percent of patients with a ≥50% reduction from baseline in frequency of headache days was significantly greater for the onabotulinumtoxinA-only group at Week 56 (69.6% O/O, 62.8% P/O; P = 0.023). "
06/01/2010 - "OnabotulinumtoxinA resulted in significant improvements compared with placebo in multiple headache symptom measures, and significantly reduced headache-related disability and improved functioning, vitality, and overall health-related quality of life. "
09/01/2013 - "The efficacy of onabotulinumtoxinA for some headaches, its long duration of action, and its favorable adverse effect profile make it a viable treatment option for the appropriate headache patients. "
08/15/2013 - "We evaluated safety and efficacy of onabotulinumtoxinA as preventive treatment of headache in CM patients with baseline MO (CM+MO) in a planned secondary analysis from two similarly designed, randomized, placebo-controlled, parallel, Phase III trials. "
02/01/2014 - "There was a reduction in the number of headache days for both onabotulinumtoxinA and saline over baseline throughout the active phases of the study. "

06/01/2015 - "This meta-analysis indicates that onabotulinumtoxinA to be an effective treatment for idiopathic overactive bladder symptoms with side effects primarily localized to urinary tract."
01/01/2012 - "Botox) provides effective treatment for overactive bladder. "
01/01/2014 - "OnabotulinumtoxinA injection is a safe and effective treatment for adults with refractory overactive bladder. "
09/01/2011 - ": The objective of the study was to evaluate the safety and efficacy of repeat intradetrusor onabotulinum toxin A injection in patients with idiopathic overactive bladder refractory to anticholinergic medications. "
11/01/2015 - "Here we present the final results from an extension study assessing long-term onabotulinumtoxinA treatment (3.5 years) in patients with idiopathic overactive bladder. "

10/01/1993 - "Botox F is an effective treatment for torticollis in patients who are immune to botox A. "
09/01/2012 - "Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia."
01/01/2001 - "A study of BTX-A demonstrated improvement of 5.15 to 10.65 degrees in head position using the Cervical Dystonia Severity Scale (CDSS) in those treated with BTX-A (trade name BOTOX) compared with placebo. "
02/15/2015 - "The Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE; NCT00836017) is a prospective, observational, multicenter, real-world registry designed to assess the safety, effectiveness, and treatment utilization following multiple treatments of onabotulinumtoxinA. "
02/15/2015 - "Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE)."